US Stock Insider Trading | Twist Bioscience Disclosed Four Insider Transactions on March 10

K-LinePoet · 2026-03-23T06:50:51+00:00

On March 10, 2026, Twist Bioscience disclosed multiple insider transactions, with director Leproust Emily M. and several executives each selling a certain number of shares on March 6, with total proceeds exceeding $200,000. Twist Bioscience focuses on providing synthetic DNA tools and serving customers across multiple sectors.

K-LinePoet

2026-03-23 06:50:51

Abstract generation in progress

On March 10, 2026, Twist Bioscience (TWST) disclosed four insider transactions. Director Emily M. Leproust sold 2,423 shares on March 6, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Director	Emily M. Leproust	March 6, 2026	Sell	2,423	46.43	$112,500
March 10, 2026	Executive	Robert F. Werner	March 6, 2026	Sell	246	46.43	$11,400
March 10, 2026	Executive	Paula Green	March 6, 2026	Sell	935	46.43	$43,400
March 10, 2026	Executive	Dennis Cho	March 6, 2026	Sell	425	46.43	$19,700
February 25, 2026	Director	Emily M. Leproust	February 23, 2026	Sell	7,205	46.71	$336,500
February 25, 2026	Executive	Dennis Cho	February 23, 2026	Sell	844	46.71	$39,400
February 25, 2026	Executive	Adam Laponis	February 23, 2026	Sell	2,085	46.71	$97,400
February 25, 2026	Executive	Robert F. Werner	February 23, 2026	Sell	1,693	46.71	$79,100
February 25, 2026	Executive	Patrick John Finn	February 23, 2026	Sell	4,294	46.71	$200,600
February 25, 2026	Executive	Paula Green	February 23, 2026	Sell	1,465	46.71	$68,400

【Company Profile】

Twist Bioscience Corporation was incorporated on February 4, 2013, in Delaware. The company is dedicated to serving customers who are working to make the world a better place. In healthcare, food/agriculture, industrial chemicals, academic research, and data storage, customers are using their synthetic DNA tools to develop methods to improve lives and enhance Earth’s sustainability. They have developed a disruptive DNA synthesis platform that enables the biological engineering industry to produce DNA for a wide range of applications and markets. By combining silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure, and e-commerce platforms, they have created an integrated technology platform.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.